Despite the lack of statistical significance in regard to the risk of cardiac or cerebrovascular events, this data suggests that following short-term administration of DAPT, monotherapy with an anti-platelet agent such as Ticagrelor has the potential to be a safer strategy than extended DAPT. However, there was no significant different in adverse cardiac, cerebrovascular events or deaths between the two groups. After one year of total treatment, patients who received Ticagrelor monotherapy experienced significantly fewer major bleeding events than those receiving DAPT. As a member of TicoThrive, you will receive a daily lesson (Monday-Friday) that will help you learn and strengthen your Spanish vocabulary and familiarize yourself with the culture and day-to-day life in Costa Rica. Patients predisposed to major bleeding events (recent traumatic brain injury, history of hemorrhagic stroke, etc.), were excluded from this study. Of the patients who completed the study, 1339 received Ticagrelor alone and 1321 received DAPT. After DES placement, patients received three months of DAPT treatment, followed by either Ticagrelor monotherapy or continued treatment with DAPT, for one year of total treatment.
TICO TRIAL TRIAL
In an effort to determine whether Ticagrelor monotherapy, as compared to a standard 1-year of DAPT following DES placement reduces the risk of adverse events, a randomized multi-center trial was conducted across 38 hospitals in South Korea. The lower risk of a net adverse clinical event (a composite of TIMI major bleeding and major adverse cardiac and cerebrovascular events) in patients treated with 3-month aspirin therapy reported from the TICO trial remained valid in patients with any of these risk factors (hazard ratio, 0.59 95 CI, 0.39-0.90 P interaction 0.74).
0 kommentar(er)
